Jpmorgan Chase & CO Belite Bio, Inc Transaction History
Jpmorgan Chase & CO
- $1.51 Trillion
- Q3 2025
A detailed history of Jpmorgan Chase & CO transactions in Belite Bio, Inc stock. As of the latest transaction made, Jpmorgan Chase & CO holds 9,809 shares of BLTE stock, worth $1.14 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
9,809
Previous 9,809
-0.0%
Holding current value
$1.14 Million
Previous $725,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
12 transactions
Others Institutions Holding BLTE
# of Institutions
36Shares Held
2.28MCall Options Held
0Put Options Held
0-
Ra Capital Management, L.P. Boston, MA875KShares$102 Million1.11% of portfolio
-
Vestal Point Capital, LP New York, NY313KShares$36.5 Million1.04% of portfolio
-
Rtw Investments, LP New York, NY313KShares$36.5 Million0.31% of portfolio
-
Soleus Capital Management, L.P. Greenwich, CT210KShares$24.5 Million0.94% of portfolio
-
Eventide Asset Management, LLC Boston, MA195KShares$22.8 Million0.27% of portfolio
About BELITE BIO, INC
- Ticker BLTE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 24,867,400
- Market Cap $2.9B
- Description
- Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery o...